Beyond dopamine: KarXT and emerging mechanism-based therapies in schizophrenia
KarXT (marketed as Cobenfy™), a fixed-dose combination of xanomeline and trospium chloride, represents the first new mechanism of action of an antipsychotic used for adult schizophrenia approved by the US Food and Drug Administration (FDA) in over 30 years. While mainstream drugs (e.g. haloperidol, chlorpromazine, risperidone, olanzapine, quetiapine, aripiprazole) mainly antagonize dopamine D2 or…
Read original article on Frontiers in Psychiatry | New and Recent Articles →Related news
-
1 Important Step in Life We Often Take Way Too Late
United States
-
Buddhism and the Serenity Prayer
United States
-
10 Essential Ways to Defend Yourself Against Negativity
United States
-
110 Funny Letter Board Quotes That Will Make You Laugh Out Loud
Sweden
-
Waking Up to Life
United States
-
The Power of Beginner’s Mind
United States
-
Maternal emotional distress, caregiving burden, and service access among mothers of children with autism spectrum disorder: a qualitative study
Switzerland
-
Trauma-informed psychological support alongside long-acting injectable buprenorphine: clients’ perspectives on the Buvidal psychological support service (BPSS) pilot in Wales
Switzerland